J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

Ollin Biosciences Launches with $100M to Challenge Roche in Eye Disease Market

Ollin Biosciences; Roche; eye disease; biotech; VEGF-A; Ang2; wet AMD; diabetic macular edema; clinical trial; OLN324; Vabysmo

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval

CSL Commits $117M for Option to Acquire VarmX and Advance Novel Blood Clotting Therapy to Market

CSL; VarmX; VMX-C001; blood clotting drug; Factor Xa inhibitors; anticoagulants; Phase 3 clinical trial; acquisition; biotech partnership; critical bleeding; FDA fast-track

FDA Crackdown on Pharma TV Ads Targets Pfizer, Novartis, BMS, Lilly & Others

FDA crackdown; pharma TV ads; Pfizer; Novartis; BMS; Lilly; warning letters; direct-to-consumer advertising; adequate provision rule; drug marketing compliance